Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 11 04:00PM ET
13.06
Dollar change
+0.57
Percentage change
4.56
%
IndexRUT P/E- EPS (ttm)-2.49 Insider Own39.82% Shs Outstand26.65M Perf Week-0.46%
Market Cap348.05M Forward P/E- EPS next Y-3.40 Insider Trans11.99% Shs Float16.04M Perf Month-16.76%
Income-66.39M PEG- EPS next Q-0.74 Inst Own47.70% Short Float4.88% Perf Quarter-5.02%
Sales0.00M P/S- EPS this Y74.09% Inst Trans- Short Ratio7.14 Perf Half Y-
Book/sh4.26 P/B3.07 EPS next Y-5.79% ROA- Short Interest0.78M Perf Year-
Cash/sh4.56 P/C2.87 EPS next 5Y- ROE- 52W Range9.00 - 22.33 Perf YTD-2.68%
Dividend Est.- P/FCF- EPS past 5Y- ROI-54.17% 52W High-41.51% Beta-
Dividend TTM- Quick Ratio7.21 Sales past 5Y19.69% Gross Margin- 52W Low45.11% ATR (14)1.26
Dividend Ex-Date- Current Ratio7.21 EPS Y/Y TTM- Oper. Margin0.00% RSI (14)40.13 Volatility10.55% 8.59%
Employees58 Debt/Eq0.10 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price21.40
Option/ShortNo / Yes LT Debt/Eq0.08 EPS Q/Q6.30% Payout- Rel Volume0.34 Prev Close12.49
Sales Surprise- EPS Surprise-23.44% Sales Q/Q-100.00% EarningsMar 11 BMO Avg Volume109.68K Price13.06
SMA20-10.95% SMA50-14.63% SMA200-8.89% Trades Volume37,009 Change4.56%
Date Action Analyst Rating Change Price Target Change
Nov-28-23Initiated Stifel Buy $20
Nov-28-23Initiated RBC Capital Mkts Outperform $22
Nov-28-23Initiated Leerink Partners Outperform $19
Nov-28-23Initiated JP Morgan Overweight $20
Nov-28-23Initiated Chardan Capital Markets Buy $23
Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The firm focuses on the medication of genetically defined cardiovascular diseases and sub-group of Alzheimer's disease. It offers LX2006 for the treatment of patients with Friedreich's ataxia, cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer's disease. The company was founded by Ronald G. Crystal in February 2017 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Longitude Capital Partners IV,10% OwnerNov 07 '23Buy11.00454,5454,999,9952,567,100Nov 09 08:32 PM
Omega Fund VI, L.P.10% OwnerNov 07 '23Buy11.00454,5454,999,9952,157,623Nov 09 08:36 PM
Lundbeckfond Invest A/S10% OwnerNov 07 '23Buy11.00227,2722,499,9921,835,959Nov 09 08:33 PM